Sodium metavanadate affected control and streptozotocin-diabetic rat liver golgi complexes

Polish Journal of Pathology

Volumn 57, Issue 2, 2006, Pages 91-97

  Da̧broś, Wojciech ^a   Goc, Anna ^b   Turyna, Bohdan ^b   Kordowiak, Anna M ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; STREPTOZOCIN; VANADATE SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DRUG ACTIVITY; ELECTRON MICROSCOPY; ENZYME BLOOD LEVEL; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GOLGI COMPLEX; LIVER STRUCTURE; MALE; MITOCHONDRIAL MEMBRANE; NONHUMAN; RAT; STREPTOZOCIN DIABETES; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CYTOPLASM; DIABETES MELLITUS, EXPERIMENTAL; DRINKING; DRUG ANTAGONISM; EATING; FEMALE; GALACTOSYLTRANSFERASES; GOLGI APPARATUS; HEPATOCYTES; HYPOGLYCEMIC AGENTS; LIVER; MICROSCOPY, ELECTRON, TRANSMISSION; ORGAN SIZE; RATS; RATS, WISTAR; VANADATES;

EID: 33748924832     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Aharon Y, Mevorach M, Shamoon H: Vanadyl sulphate does not enhance insulin action in patients with type 1 diabetes. Diabetes care 1998, 21, 2194-2195.
2. Badmaev V, Prakash S, Majeed M: Vanadium: A review of its potential role in the fight against diabetes. J Alternat Complement Med 1999, 5, 273-291.
3. Brichard SM, Henquin JC: The role of vanadium in the management of diabetes. Trends Pharmacol Sci 1995, 16, 265-270.
4. Cam MC, Pederson RA, Brownsey RW, McNeill JH: Long-term effectiveness of oral vanadyl sulphate in streptozotocin-diabetic rats. Diabetologia 1993, 36, 218-224.
5. Cam MC, Brownsey RW, McNeill JH: Mechanism of vanadium action: insulin-mimetic or insulin enhancing agent. Can J Physiol Pharmacol 2000, 78, 829-847.
6. Candura SM, Manzo L, Marraccini P, Coccini T, Tononi M: Investigation into vanadate-induced potentiation of smooth muscle contractility in the rabbit. Life Sci 1993, 54, 237-244.
7. Da̧broś W, Dziga D, Grybós R, Kordowiak AM: Biochemical and morphological alterations in rat liver Golgi complexes after treatment with bis(maltolato)oxovanadium (IV) [BMOV] or maltol alone. Pathol Res Pract 2000, 196, 561-568.
8. 4] on biochemical activity and morphology of control and streptozotocin-diabetic rat liver Golgi complexes. Pol J Pathol 2004, 55, 25-32.
9. Domingo JL: Vanadium and diabetes. What about vanadium toxicity. Mol Cell Biochem 2000, 203, 185-187.
10. Domingo JL: Vanadium and tungsten derivatives as antidiabetic agents. A review of their toxic effects. Biol Trace Element Res 2002, 88, 97-112.
11. Fawcett JP, Farquhar SJ, Thou T, Shand BI: Oral vanadyl sulphate does not affect blood cells, viscosity or biochemistry in humans. Pharmacol Toxicol 1997, 80, 202-206.
12. Fleischer B: Isolation and characterisation of Golgi apparatus and membranes from rat liver. In: Methods in Enzymology. Fleischer S, Racker L, eds. Acad Press Inc New York 1974, 31A, pp180-191.
13. rd ed. 1988, 1, pp329-412.
14. Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlanc R, Landaker EJ, Jiang ZY, Willsky GR, Kahn CR: Metabolic effects of vanadyl sulphate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. Metabolism 2000, 49, 400-410.
15. Karnovsky MJ: A formaldehyde-glutaraldehyde fixative of high osmolarity for use in electron microscopy. J Cell Biol 1965, 27, 137A-138A.
16. Khendelwal RL, Pugazhenthi S: Vanadium as a potential therapeutic agent for the treatment of diabetes mellitus. Metal Ions in Biology and Med. Callery P, Corbella J, Domingo JL, Ethienne JC, Llobet JM, Libbey J, eds. Eurotext Paris 1996, 4, 673-675.
17. Kordowiak AM, Trzos R, Gryboś R: Insulin-like effects on liver Golgi membrane preparations of bis(oxalato)oxovanadate(IV) complex ion, a new vanadate compound. Horm Metab Res 1997, 29, 104-108.
18. 2O. Part I. One week treatment with vanadium compound. Pol J Pathol 2000, 51, 9-16.
19. Kordowiak AM, Da̧broś W, Kajda B: The influence of a new vanadium complex, bis(2,2′-bipyridine)oxovanadium(IV) sulphate on liver Golgi complexes from control and streptozotocin-diabetic rats. Horm Metab Res 2002, 34, 556-560.
20. Kordowiak AM, Dziga D, Da̧broś W: Streptozotocin-induced alterations of rat liver Golgi complexes are ameliorated by BMOV [bis(maltolato)oxovanadium(IV)] activity. Horm Metab Res 2004, 36, 148-154.
21. Kordowiak AM, Goc A, Drozdowska E, Turyna B, Da̧broś W: Sodium orthovanadate exerts influence on liver Golgi complexes from control and streptozotocin-diabetic rats. J Inorg Biochem 2005, 99, 1083-1089.
22. Li SH, McNeill JH: In vivo effects of vanadium on GLUT4 translocation in cardiac tissue of STZ-diabetic rats. Mol Cell Biochem 2001, 217, 121-129.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with Folin phenol reagent. J Biol Chem 1951, 193, 265-275.
24. McNeill JH, Battell M, Cam M, Dai S, Thompson K, Yuen VG: Oral vanadium and lowering of blood glucose. Diabetes 1994, 43, 1268-1270.
25. Marzban L, Bhanot S, McNeill JH: In vivo effects of insulin and bis(maltolato)oxo-vanadium(IV) on PKB activity in the skeletal muscle and liver of diabetic rats. Mol Cell Biochem 2001, 223, 147-157.
26. Poucheret P, Verma S, Grynpas MD, McNeill JH: Vanadium and diabetes. Mol Cell Biochem 1998, 188, 73-80.
27. Pugazhenthi S, Khendelwal RL: Insulin-like effects of vanadate on hepatic glycogen metabolism in nondiabetic and streptozotocin-induced diabetic rats. Diabetes 1990, 39, 821-827
28. Reul BA, Amin SS, Buchet JP, Ongemba LN, Crans DC, Brichard SM: Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats. Brit J Pharmacol 1999, 126, 467-477.
29. Sarnecka-Keller M, Kordowiak A: The activity of Golgi membrane galactosyl transferase EC 2.4.1.38 in the livers of streptozotocin diabetic rats. Acta Biochim Polon 1977, 24, 179-185.
30. Shechter Y: Insulin-mimetic effects of vanadate. Possible implications for further treatment of diabetes. Diabetes 1990, 39, 1-5.
31. Somogyi MJ, Nelson N: Determination of reducing sugars and carbohydrates. In: Whistler R, Wolprom R eds. Methods in Carbohydrate Chemistry Acad Press Inc, New York, London 1962, 1, 380-394.
32. 2) coordination mode. J Inorg Biochem 2001, 86, 179-186.
33. Tsiani E, Fantus IG: Vanadium compounds. Biological actions and potential as pharmacological agents. Trends Endocrinol Metab 1997, 8, 51-58.
34. Venable JH, Coggeshall RA: Simplified lead citrate stain for use in electron microscopy. J Cell Biol 1966, 25, 407-408.
35. Woo LCY, Yuen VG, Thompson KH: Vanadyl-biquanide complexes as potential synergistic insulin mimics. J Inorg Biochem 1999, 76, 251-257.
36. Yao J, Battell ML, McNeill JH: Acute and chronic response to vanadium following two methods of streptozotocin-diabetes induction. Can J Physiol Pharmacol 1997, 75, 83-90.
37. Yuen VG, Orvig C, McNeill JH: Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV). Can J Physiol Pharmacol 1993, 71, 263-269.
38. Yuen VG, Orvig C, Thompson KH, McNeill JH: Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxo-vanadium(IV). Can J Physiol Pharmacol 1993, 71, 270-276.
39. Yuen VG, Caravan P, Gelmini L, Glover N, McNeill JH, Setyawati IA, Zhou R, Orvig C: Glucose lowering properties of vanadium compounds. Comparison of coordination complexes with maltol or kojic acid as ligands. J Inorg Biochem 1997, 68, 109-116.